SK13598A3 - Benzimidazole compounds - Google Patents

Benzimidazole compounds Download PDF

Info

Publication number: SK13598A3
Authority: SK; Slovakia
Prior art keywords: group; benzimidazole; compound; carboxamide; alkyl
Prior art date: 1995-08-02

Application number

SK135-98A

Other languages

English (en)

Slovak (sk)

Inventor

Roger J Griffin

Alan H Calvert

Nicola J Curtin

David R Newell

Bernard T Golding

Original Assignee

Univ Newcastle Ventures Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-08-02

Filing date

1996-07-30

Publication date

1998-06-03

1995-08-02 Priority claimed from GBGB9515843.2A external-priority patent/GB9515843D0/en

1996-05-30 Priority claimed from GBGB9611245.3A external-priority patent/GB9611245D0/en

1996-07-30 Application filed by Univ Newcastle Ventures Ltd filed Critical Univ Newcastle Ventures Ltd

1998-06-03 Publication of SK13598A3 publication Critical patent/SK13598A3/sk

Links

125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title claims description 4
150000001875 compounds Chemical class 0.000 claims abstract description 154
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 88
125000000217 alkyl group Chemical group 0.000 claims abstract description 55
-1 CH2CH2OH) Chemical class 0.000 claims abstract description 51
102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 claims abstract description 43
229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims abstract description 40
101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 claims abstract description 38
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 31
239000001257 hydrogen Substances 0.000 claims abstract description 27
125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 27
108090000790 Enzymes Proteins 0.000 claims abstract description 19
102000004190 Enzymes Human genes 0.000 claims abstract description 19
239000000651 prodrug Substances 0.000 claims abstract description 19
229940002612 prodrug Drugs 0.000 claims abstract description 19
JJDMKDXGNVJWCD-UHFFFAOYSA-N 1h-benzimidazole-4-carboxamide Chemical class NC(=O)C1=CC=CC2=C1N=CN2 JJDMKDXGNVJWCD-UHFFFAOYSA-N 0.000 claims abstract description 15
239000003814 drug Substances 0.000 claims abstract description 15
230000000694 effects Effects 0.000 claims abstract description 15
125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract description 15
125000002252 acyl group Chemical group 0.000 claims abstract description 10
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 10
150000003839 salts Chemical class 0.000 claims abstract description 10
230000001225 therapeutic effect Effects 0.000 claims abstract description 10
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims abstract description 9
125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 9
125000003107 substituted aryl group Chemical group 0.000 claims abstract description 9
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims abstract description 8
238000001959 radiotherapy Methods 0.000 claims abstract description 8
102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims abstract description 3
108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims abstract description 3
238000002360 preparation method Methods 0.000 claims description 71
229910052757 nitrogen Inorganic materials 0.000 claims description 47
238000000034 method Methods 0.000 claims description 45
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 33
239000000203 mixture Substances 0.000 claims description 30
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 25
125000001424 substituent group Chemical group 0.000 claims description 23
230000002401 inhibitory effect Effects 0.000 claims description 22
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 21
125000003545 alkoxy group Chemical group 0.000 claims description 20
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 20
125000003118 aryl group Chemical group 0.000 claims description 14
229940127089 cytotoxic agent Drugs 0.000 claims description 12
230000008569 process Effects 0.000 claims description 12
238000002560 therapeutic procedure Methods 0.000 claims description 11
229910052736 halogen Inorganic materials 0.000 claims description 10
239000008194 pharmaceutical composition Substances 0.000 claims description 10
150000003536 tetrazoles Chemical class 0.000 claims description 10
239000003795 chemical substances by application Substances 0.000 claims description 9
150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 9
KKTUQAYCCLMNOA-UHFFFAOYSA-N 2,3-diaminobenzoic acid Chemical compound NC1=CC=CC(C(O)=O)=C1N KKTUQAYCCLMNOA-UHFFFAOYSA-N 0.000 claims description 8
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 8
125000003368 amide group Chemical group 0.000 claims description 8
239000002254 cytotoxic agent Substances 0.000 claims description 8
108010049290 ADP Ribose Transferases Proteins 0.000 claims description 7
230000005764 inhibitory process Effects 0.000 claims description 7
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
241000124008 Mammalia Species 0.000 claims description 6
125000004647 alkyl sulfenyl group Chemical group 0.000 claims description 6
125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 6
125000004432 carbon atom Chemical group C* 0.000 claims description 6
MKRGNKRNZLHINT-UHFFFAOYSA-N 2-(4-methoxyphenyl)-1h-benzimidazole-4-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=CC(C(N)=O)=C2N1 MKRGNKRNZLHINT-UHFFFAOYSA-N 0.000 claims description 5
JCMGIFLIMIXLTP-UHFFFAOYSA-N 2-methyl-1h-benzimidazole-4-carboxamide Chemical compound C1=CC(C(N)=O)=C2NC(C)=NC2=C1 JCMGIFLIMIXLTP-UHFFFAOYSA-N 0.000 claims description 5
OBBJGEVEIULNEO-UHFFFAOYSA-N 2-phenyl-1h-benzimidazole-4-carboxamide Chemical compound N=1C=2C(C(=O)N)=CC=CC=2NC=1C1=CC=CC=C1 OBBJGEVEIULNEO-UHFFFAOYSA-N 0.000 claims description 5
102000009062 ADP Ribose Transferases Human genes 0.000 claims description 5
229910019142 PO4 Inorganic materials 0.000 claims description 5
150000001408 amides Chemical class 0.000 claims description 5
125000006267 biphenyl group Chemical group 0.000 claims description 5
150000002367 halogens Chemical class 0.000 claims description 5
NVVWVYYHTKCIAE-UHFFFAOYSA-N 2-(3'-methoxyphenyl) benzimidazole-4-carboxamide Chemical compound COC1=CC=CC(C=2NC3=CC=CC(=C3N=2)C(N)=O)=C1 NVVWVYYHTKCIAE-UHFFFAOYSA-N 0.000 claims description 4
VANPTVOCOWCFLO-UHFFFAOYSA-N 2-(trifluoromethyl)-1h-benzimidazole-4-carboxamide Chemical compound NC(=O)C1=CC=CC2=C1NC(C(F)(F)F)=N2 VANPTVOCOWCFLO-UHFFFAOYSA-N 0.000 claims description 4
KXFVEKRQOAGNIL-UHFFFAOYSA-N 2-(4-methoxyphenyl)-n-methyl-1h-benzimidazole-4-carboxamide Chemical compound N1C=2C(C(=O)NC)=CC=CC=2N=C1C1=CC=C(OC)C=C1 KXFVEKRQOAGNIL-UHFFFAOYSA-N 0.000 claims description 3
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 3
230000000259 anti-tumor effect Effects 0.000 claims description 3
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
238000001990 intravenous administration Methods 0.000 claims description 3
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
239000008186 active pharmaceutical agent Substances 0.000 claims description 2
125000005907 alkyl ester group Chemical group 0.000 claims description 2
125000001589 carboacyl group Chemical group 0.000 claims description 2
231100000599 cytotoxic agent Toxicity 0.000 claims description 2
239000002552 dosage form Substances 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
150000002431 hydrogen Chemical group 0.000 claims 13
125000005843 halogen group Chemical group 0.000 claims 5
239000010452 phosphate Substances 0.000 claims 4
229910000318 alkali metal phosphate Chemical class 0.000 claims 2
125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 2
125000000539 amino acid group Chemical group 0.000 claims 2
ZRIUUUJAJJNDSS-UHFFFAOYSA-N ammonium phosphates Chemical class [NH4+].[NH4+].[NH4+].[O-]P([O-])([O-])=O ZRIUUUJAJJNDSS-UHFFFAOYSA-N 0.000 claims 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 claims 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
125000006356 alkylene carbonyl group Chemical group 0.000 claims 1
238000011319 anticancer therapy Methods 0.000 claims 1
239000004305 biphenyl Substances 0.000 claims 1
235000010290 biphenyl Nutrition 0.000 claims 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
RQKYHDHLEMEVDR-UHFFFAOYSA-N oxo-bis(phenylmethoxy)phosphanium Chemical compound C=1C=CC=CC=1CO[P+](=O)OCC1=CC=CC=C1 RQKYHDHLEMEVDR-UHFFFAOYSA-N 0.000 claims 1
229940079593 drug Drugs 0.000 abstract description 11
230000001472 cytotoxic effect Effects 0.000 abstract description 9
230000003389 potentiating effect Effects 0.000 abstract description 9
231100000433 cytotoxic Toxicity 0.000 abstract description 8
239000003112 inhibitor Substances 0.000 abstract description 4
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 abstract 1
102000011724 DNA Repair Enzymes Human genes 0.000 abstract 1
108010076525 DNA Repair Enzymes Proteins 0.000 abstract 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 108
239000000243 solution Substances 0.000 description 64
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 63
229910052799 carbon Inorganic materials 0.000 description 45
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
210000004027 cell Anatomy 0.000 description 40
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
239000007787 solid Substances 0.000 description 38
238000012360 testing method Methods 0.000 description 37
IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
239000000047 product Substances 0.000 description 30
238000002844 melting Methods 0.000 description 29
230000008018 melting Effects 0.000 description 29
239000002904 solvent Substances 0.000 description 29
238000004458 analytical method Methods 0.000 description 27
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 25
239000011541 reaction mixture Substances 0.000 description 24
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 20
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 18
238000010561 standard procedure Methods 0.000 description 18
239000012661 PARP inhibitor Substances 0.000 description 17
229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 17
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
229950006238 nadide Drugs 0.000 description 15
239000002253 acid Substances 0.000 description 14
238000001953 recrystallisation Methods 0.000 description 14
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 13
BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 12
229960000583 acetic acid Drugs 0.000 description 12
JWODGKSSAMJXMR-UHFFFAOYSA-N 4,5-dioxo-1-propan-2-ylpyrrolidine-3-carbonitrile Chemical compound CC(C)N1CC(C#N)C(=O)C1=O JWODGKSSAMJXMR-UHFFFAOYSA-N 0.000 description 11
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 11
238000004440 column chromatography Methods 0.000 description 11
229960004964 temozolomide Drugs 0.000 description 11
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
108091034117 Oligonucleotide Proteins 0.000 description 10
238000003556 assay Methods 0.000 description 10
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 10
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
229910002091 carbon monoxide Inorganic materials 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
239000002244 precipitate Substances 0.000 description 9
238000010992 reflux Methods 0.000 description 9
150000001556 benzimidazoles Chemical class 0.000 description 8
239000000872 buffer Substances 0.000 description 8
238000001914 filtration Methods 0.000 description 8
239000012362 glacial acetic acid Substances 0.000 description 8
230000008439 repair process Effects 0.000 description 8
239000002246 antineoplastic agent Substances 0.000 description 7
150000003936 benzamides Chemical class 0.000 description 7
239000003054 catalyst Substances 0.000 description 7
238000003756 stirring Methods 0.000 description 7
230000004083 survival effect Effects 0.000 description 7
229960000549 4-dimethylaminophenol Drugs 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
108020004414 DNA Proteins 0.000 description 6
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
159000000021 acetate salts Chemical class 0.000 description 6
239000006285 cell suspension Substances 0.000 description 6
239000013078 crystal Substances 0.000 description 6
230000003013 cytotoxicity Effects 0.000 description 6
231100000135 cytotoxicity Toxicity 0.000 description 6
239000000706 filtrate Substances 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
239000000543 intermediate Substances 0.000 description 6
150000004702 methyl esters Chemical class 0.000 description 6
102000053602 DNA Human genes 0.000 description 5
229910021529 ammonia Inorganic materials 0.000 description 5
238000009835 boiling Methods 0.000 description 5
KOUGHMOSYJCJLE-UHFFFAOYSA-N chembl131719 Chemical compound N=1C=2C(C(=O)N)=CC=CC=2NC=1C1=CC=C(O)C=C1 KOUGHMOSYJCJLE-UHFFFAOYSA-N 0.000 description 5
238000001816 cooling Methods 0.000 description 5
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
229910000041 hydrogen chloride Inorganic materials 0.000 description 5
229910052943 magnesium sulfate Inorganic materials 0.000 description 5
235000019341 magnesium sulphate Nutrition 0.000 description 5
239000000463 material Substances 0.000 description 5
239000002243 precursor Substances 0.000 description 5
230000005855 radiation Effects 0.000 description 5
FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 5
229940048086 sodium pyrophosphate Drugs 0.000 description 5
235000019818 tetrasodium diphosphate Nutrition 0.000 description 5
239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 5
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
230000005526 G1 to G0 transition Effects 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000012043 crude product Substances 0.000 description 4
230000006378 damage Effects 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
238000001704 evaporation Methods 0.000 description 4
230000008020 evaporation Effects 0.000 description 4
238000009472 formulation Methods 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
230000009467 reduction Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
VVQNAFBGAWCMLU-UHFFFAOYSA-N 1h-benzimidazole-4-carboxylic acid Chemical compound OC(=O)C1=CC=CC2=C1N=CN2 VVQNAFBGAWCMLU-UHFFFAOYSA-N 0.000 description 3
HRZOSZZKYDGKSC-UHFFFAOYSA-N 2-(4-cyanophenyl)-1h-benzimidazole-4-carboxamide Chemical compound N1C=2C(C(=O)N)=CC=CC=2N=C1C1=CC=C(C#N)C=C1 HRZOSZZKYDGKSC-UHFFFAOYSA-N 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
LVUZVFVJPPDROZ-UHFFFAOYSA-N 2-methyl-1h-benzimidazole-4-carboxylic acid Chemical compound C1=CC(C(O)=O)=C2NC(C)=NC2=C1 LVUZVFVJPPDROZ-UHFFFAOYSA-N 0.000 description 3
VKPLPDIMEREJJF-UHFFFAOYSA-N 3-methoxybenzamide Chemical compound COC1=CC=CC(C(N)=O)=C1 VKPLPDIMEREJJF-UHFFFAOYSA-N 0.000 description 3
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
230000005778 DNA damage Effects 0.000 description 3
231100000277 DNA damage Toxicity 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
108091026813 Poly(ADPribose) Proteins 0.000 description 3
235000011114 ammonium hydroxide Nutrition 0.000 description 3
229910052786 argon Inorganic materials 0.000 description 3
230000005025 clonogenic survival Effects 0.000 description 3
238000001035 drying Methods 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
238000009650 gentamicin protection assay Methods 0.000 description 3
230000009036 growth inhibition Effects 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
239000002609 medium Substances 0.000 description 3
VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 3
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
239000012044 organic layer Substances 0.000 description 3
229910052763 palladium Inorganic materials 0.000 description 3
239000008188 pellet Substances 0.000 description 3
239000004033 plastic Substances 0.000 description 3
CORDOWZJZKLEHO-UHFFFAOYSA-N 2-(4-aminophenyl)-1h-benzimidazole-4-carboxamide Chemical compound N1C=2C(C(=O)N)=CC=CC=2N=C1C1=CC=C(N)C=C1 CORDOWZJZKLEHO-UHFFFAOYSA-N 0.000 description 2
OUYLJUGKAHFFAR-UHFFFAOYSA-N 2-(4-methoxyphenyl)-1-methylbenzimidazole-4-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=NC2=C(C(N)=O)C=CC=C2N1C OUYLJUGKAHFFAR-UHFFFAOYSA-N 0.000 description 2
AXPSEYPVFKMYID-UHFFFAOYSA-N 2-(4-nitrophenyl)-1h-benzimidazole-4-carboxamide Chemical compound N1C=2C(C(=O)N)=CC=CC=2N=C1C1=CC=C([N+]([O-])=O)C=C1 AXPSEYPVFKMYID-UHFFFAOYSA-N 0.000 description 2
BWXFCEOBQGOLJF-UHFFFAOYSA-N 2-[3-(trifluoromethyl)phenyl]-1h-benzimidazole-4-carboxamide Chemical compound N1C=2C(C(=O)N)=CC=CC=2N=C1C1=CC=CC(C(F)(F)F)=C1 BWXFCEOBQGOLJF-UHFFFAOYSA-N 0.000 description 2
JJPIVRWTAGQTPQ-UHFFFAOYSA-N 2-amino-3-nitrobenzoic acid Chemical compound NC1=C(C(O)=O)C=CC=C1[N+]([O-])=O JJPIVRWTAGQTPQ-UHFFFAOYSA-N 0.000 description 2
LZGYSXDYTDCYCR-UHFFFAOYSA-N 2-phenyl-1h-benzimidazole-4-carboxylic acid Chemical compound N=1C=2C(C(=O)O)=CC=CC=2NC=1C1=CC=CC=C1 LZGYSXDYTDCYCR-UHFFFAOYSA-N 0.000 description 2
GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 2
NGMMGKYJUWYIIG-UHFFFAOYSA-N 3-hydroxybenzamide Chemical compound NC(=O)C1=CC=CC(O)=C1 NGMMGKYJUWYIIG-UHFFFAOYSA-N 0.000 description 2
GMOAOEGBMSRFFQ-UHFFFAOYSA-N 3-nitrobenzene-1,2-dicarboxamide Chemical compound NC(=O)C1=CC=CC([N+]([O-])=O)=C1C(N)=O GMOAOEGBMSRFFQ-UHFFFAOYSA-N 0.000 description 2
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
239000005711 Benzoic acid Substances 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
239000012190 activator Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
150000003857 carboxamides Chemical class 0.000 description 2
230000032823 cell division Effects 0.000 description 2
239000003610 charcoal Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
229940044683 chemotherapy drug Drugs 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
239000003636 conditioned culture medium Substances 0.000 description 2
229940043239 cytotoxic antineoplastic drug Drugs 0.000 description 2
238000002784 cytotoxicity assay Methods 0.000 description 2
231100000263 cytotoxicity test Toxicity 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
239000003480 eluent Substances 0.000 description 2
238000010828 elution Methods 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000000284 extract Substances 0.000 description 2
230000005251 gamma ray Effects 0.000 description 2
239000007789 gas Substances 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000002198 insoluble material Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
SRZIRRABHYIAFR-UHFFFAOYSA-N methyl 2-[3-(trifluoromethyl)phenyl]-1h-benzimidazole-4-carboxylate Chemical compound N=1C=2C(C(=O)OC)=CC=CC=2NC=1C1=CC=CC(C(F)(F)F)=C1 SRZIRRABHYIAFR-UHFFFAOYSA-N 0.000 description 2
HDCLJQZLTMJECA-UHFFFAOYSA-N methyl 2-amino-3-nitrobenzoate Chemical compound COC(=O)C1=CC=CC([N+]([O-])=O)=C1N HDCLJQZLTMJECA-UHFFFAOYSA-N 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000003439 radiotherapeutic effect Effects 0.000 description 2
238000010898 silica gel chromatography Methods 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000005292 vacuum distillation Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
KRCCCWVXRVDONW-UHFFFAOYSA-N 1,3-benzoxazole-4-carboxylic acid Chemical compound OC(=O)C1=CC=CC2=C1N=CO2 KRCCCWVXRVDONW-UHFFFAOYSA-N 0.000 description 1
XIQDETZLOXHMNE-UHFFFAOYSA-N 1-benzoyl-2-(4-methoxyphenyl)benzimidazole-4-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=NC2=C(C(N)=O)C=CC=C2N1C(=O)C1=CC=CC=C1 XIQDETZLOXHMNE-UHFFFAOYSA-N 0.000 description 1
XIZCDQOKKYYCRH-UHFFFAOYSA-N 1h-benzimidazole-2-carboxamide Chemical class C1=CC=C2NC(C(=O)N)=NC2=C1 XIZCDQOKKYYCRH-UHFFFAOYSA-N 0.000 description 1
MXIUWSYTQJLIKE-UHFFFAOYSA-N 2-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=CC=C1C(Cl)=O MXIUWSYTQJLIKE-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
IGLWGHRTQOYFDV-UHFFFAOYSA-N 2-carbamoyl-3-nitrobenzoic acid Chemical compound NC(=O)C1=C(C(O)=O)C=CC=C1[N+]([O-])=O IGLWGHRTQOYFDV-UHFFFAOYSA-N 0.000 description 1
RUJYJCANMOTJMO-UHFFFAOYSA-N 3-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=CC(C(Cl)=O)=C1 RUJYJCANMOTJMO-UHFFFAOYSA-N 0.000 description 1
RUQIUASLAXJZIE-UHFFFAOYSA-N 3-methoxybenzoyl chloride Chemical compound COC1=CC=CC(C(Cl)=O)=C1 RUQIUASLAXJZIE-UHFFFAOYSA-N 0.000 description 1
AFPHTEQTJZKQAQ-UHFFFAOYSA-N 3-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1 AFPHTEQTJZKQAQ-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
OXZYBOLWRXENKT-UHFFFAOYSA-N 4-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=C(C(Cl)=O)C=C1 OXZYBOLWRXENKT-UHFFFAOYSA-N 0.000 description 1
USEDMAWWQDFMFY-UHFFFAOYSA-N 4-cyanobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(C#N)C=C1 USEDMAWWQDFMFY-UHFFFAOYSA-N 0.000 description 1
ROFZMKDROVBLNY-UHFFFAOYSA-N 4-nitro-2-benzofuran-1,3-dione Chemical compound [O-][N+](=O)C1=CC=CC2=C1C(=O)OC2=O ROFZMKDROVBLNY-UHFFFAOYSA-N 0.000 description 1
SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 1
SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical group C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
102100036883 Cyclin-H Human genes 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
239000012623 DNA damaging agent Substances 0.000 description 1
230000033616 DNA repair Effects 0.000 description 1
230000008265 DNA repair mechanism Effects 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101000713120 Homo sapiens Cyclin-H Proteins 0.000 description 1
101001113483 Homo sapiens Poly [ADP-ribose] polymerase 1 Proteins 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
WOWKKVDJPNTQPU-UHFFFAOYSA-N N.OF Chemical compound N.OF WOWKKVDJPNTQPU-UHFFFAOYSA-N 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
108091081548 Palindromic sequence Proteins 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
SARKQAUWTBDBIZ-UHFFFAOYSA-N azane;2-carbamoylbenzoic acid Chemical compound [NH4+].NC(=O)C1=CC=CC=C1C([O-])=O SARKQAUWTBDBIZ-UHFFFAOYSA-N 0.000 description 1
150000007514 bases Chemical group 0.000 description 1
229940054066 benzamide antipsychotics Drugs 0.000 description 1
230000027455 binding Effects 0.000 description 1
238000006065 biodegradation reaction Methods 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
239000012267 brine Substances 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000007810 chemical reaction solvent Substances 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
230000005757 colony formation Effects 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000007596 consolidation process Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000012937 correction Methods 0.000 description 1
239000013058 crude material Substances 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
230000030609 dephosphorylation Effects 0.000 description 1
238000006209 dephosphorylation reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000012470 diluted sample Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004821 distillation Methods 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000005918 in vitro anti-tumor Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
230000005865 ionizing radiation Effects 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
UZMYAXZLWVFGBD-UHFFFAOYSA-N methyl 1h-benzimidazole-4-carboxylate Chemical compound COC(=O)C1=CC=CC2=C1N=CN2 UZMYAXZLWVFGBD-UHFFFAOYSA-N 0.000 description 1
ALVVOMBQFRXMLU-UHFFFAOYSA-N methyl 2-(3-methoxyphenyl)-1h-benzimidazole-4-carboxylate Chemical compound N=1C=2C(C(=O)OC)=CC=CC=2NC=1C1=CC=CC(OC)=C1 ALVVOMBQFRXMLU-UHFFFAOYSA-N 0.000 description 1
ITDKTMIMXOUXFS-UHFFFAOYSA-N methyl 2-(4-cyanophenyl)-1h-benzimidazole-4-carboxylate Chemical compound N=1C=2C(C(=O)OC)=CC=CC=2NC=1C1=CC=C(C#N)C=C1 ITDKTMIMXOUXFS-UHFFFAOYSA-N 0.000 description 1
DOTKOAHLDHXKOF-UHFFFAOYSA-N methyl 2-(4-methoxyphenyl)-1h-benzimidazole-4-carboxylate Chemical compound N=1C=2C(C(=O)OC)=CC=CC=2NC=1C1=CC=C(OC)C=C1 DOTKOAHLDHXKOF-UHFFFAOYSA-N 0.000 description 1
VJYYVNCEXMNMJO-UHFFFAOYSA-N methyl 2-(4-nitrophenyl)-1h-benzimidazole-4-carboxylate Chemical compound N=1C=2C(C(=O)OC)=CC=CC=2NC=1C1=CC=C([N+]([O-])=O)C=C1 VJYYVNCEXMNMJO-UHFFFAOYSA-N 0.000 description 1
HGDDYLPGUIZRHE-UHFFFAOYSA-N methyl 2-phenyl-1h-benzimidazole-4-carboxylate Chemical compound N1C=2C(C(=O)OC)=CC=CC=2N=C1C1=CC=CC=C1 HGDDYLPGUIZRHE-UHFFFAOYSA-N 0.000 description 1
239000012022 methylating agents‎ Substances 0.000 description 1
230000001035 methylating effect Effects 0.000 description 1
239000013081 microcrystal Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229960003966 nicotinamide Drugs 0.000 description 1
235000005152 nicotinamide Nutrition 0.000 description 1
239000011570 nicotinamide Substances 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
229910000069 nitrogen hydride Inorganic materials 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
235000011837 pasties Nutrition 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
230000035699 permeability Effects 0.000 description 1
230000008823 permeabilization Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000005731 poly ADP ribosylation Effects 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920000137 polyphosphoric acid Polymers 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000009290 primary effect Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000002002 slurry Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000010998 test method Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
238000001665 trituration Methods 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/10—Radicals substituted by halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Data Exchanges In Wide-Area Networks (AREA)

SK135-98A 1995-08-02 1996-07-30 Benzimidazole compounds SK13598A3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9515843.2A GB9515843D0 (en)	1995-08-02	1995-08-02	Benzimidazole compounds
GBGB9611245.3A GB9611245D0 (en)	1996-05-30	1996-05-30	Benzimidazole compounds
PCT/GB1996/001832 WO1997004771A1 (en)	1995-08-02	1996-07-30	Benzimidazole compounds

Publications (1)

Publication Number	Publication Date
SK13598A3 true SK13598A3 (en)	1998-06-03

Family

ID=26307504

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK135-98A SK13598A3 (en)	1995-08-02	1996-07-30	Benzimidazole compounds

Country Status (26)

Country	Link
US (2)	US6100283A (zh)
EP (1)	EP0841924B1 (zh)
JP (1)	JPH11510154A (zh)
KR (1)	KR100447539B1 (zh)
CN (1)	CN1159007C (zh)
AP (1)	AP866A (zh)
AT (1)	ATE225173T1 (zh)
AU (1)	AU714873B2 (zh)
BR (1)	BR9610051A (zh)
CA (1)	CA2225465A1 (zh)
CZ (1)	CZ30398A3 (zh)
DE (1)	DE69624115T2 (zh)
DK (1)	DK0841924T3 (zh)
EA (1)	EA000999B1 (zh)
ES (1)	ES2183004T3 (zh)
HU (1)	HUP9901092A3 (zh)
IL (1)	IL123147A (zh)
MX (1)	MX9800927A (zh)
NO (1)	NO317033B1 (zh)
NZ (1)	NZ313713A (zh)
OA (1)	OA10661A (zh)
PL (1)	PL324869A1 (zh)
PT (1)	PT841924E (zh)
SK (1)	SK13598A3 (zh)
TR (1)	TR199800127T1 (zh)
WO (1)	WO1997004771A1 (zh)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2776291B1 (fr) *	1998-03-18	2000-06-16	Pf Medicament	Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament
US6919366B2 (en) *	1998-05-22	2005-07-19	Avanir Pharmaceuticals	Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) *	1998-05-22	2005-06-28	Avanir Pharmaceuticals	Benzimidazole compounds for regulating IgE
UA65635C2 (uk)	1998-09-03	2004-04-15	Н-Гене Кутато Кфт.	НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ
ES2234318T3 (es)	1998-11-03	2005-06-16	ABBOTT GMBH & CO. KG	2-fenil-benzimidazoles sustituidos, su preparacion y uso.
DK1131301T3 (da) *	1998-11-17	2006-01-09	Abbott Gmbh & Co Kg	2-phenylbenzimidazoler og 2-phenylindoler, fremstilling af anvendelse heraf
DE19916460B4 (de) *	1999-04-12	2006-12-21	Abbott Gmbh & Co. Kg	Substituierte Benzimidazole, deren Herstellung und Anwendung
PT1133477E (pt)	1998-11-27	2004-06-30	Abbott Gmbh & Co Kg	Benzimidazois substituidos e a utilizacao dos mesmos como inibidores da parp
SK287338B6 (sk)	1999-01-11	2010-07-07	Agouron Pharmaceuticals, Inc.	Tricyklická zlúčenina, jej použitie a farmaceutická kompozícia s jej obsahom
FR2788518B1 (fr) *	1999-01-14	2001-03-02	Centre Nat Rech Scient	Nouveaux carbamates actives stables, leur procede de preparation et leur utilisation pour la preparation d'urees
DE19918211A1 (de) *	1999-04-22	2000-10-26	Basf Ag	Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
DE19920936A1 (de) *	1999-05-07	2000-11-09	Basf Ag	Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
ECSP003637A (es)	1999-08-31	2002-03-25	Agouron Pharma	Inhibidores triciclicos de poli (adp-ribosa) polimerasas
AU7314200A (en) *	1999-09-17	2001-04-24	Yamanouchi Pharmaceutical Co., Ltd.	Benzimidazole derivatives
DE19946289A1 (de) *	1999-09-28	2001-03-29	Basf Ag	Benzodiazepin-Derivate, deren Herstellung und Anwendung
US6759425B2 (en)	1999-10-21	2004-07-06	Avanir Pharmaceuticals	Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
IT1315267B1 (it) *	1999-12-23	2003-02-03	Novuspharma Spa	Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
AU2001240542A1 (en)	2000-02-01	2001-08-14	Basf Aktiengesellschaft	Heterocyclic compounds and their use as parp inhibitors
DE10021468A1 (de) *	2000-05-04	2001-11-08	Basf Ag	Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen
DE10022925A1 (de) *	2000-05-11	2001-11-15	Basf Ag	Substituierte Indole als PARP-Inhibitoren
CZ20032691A3 (en) *	2001-03-12	2004-04-14	Avanir Pharmaceuticals	Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
US7072771B2 (en) *	2001-06-07	2006-07-04	University Of Kentucky Research Foundation	Selective PARP-1 targeting for designing chemo/radio sensitizing agents
WO2003020698A2 (en) *	2001-09-06	2003-03-13	Prochon Biotech Ltd.	Protein tyrosine kinase inhibitors
DE10201240A1 (de) *	2002-01-15	2003-07-24	Bayer Ag	Substituierte Alkyluracile und ihre Verwendung
TW200304820A (en) *	2002-03-25	2003-10-16	Avanir Pharmaceuticals	Use of benzimidazole analogs in the treatment of cell proliferation
US20040034078A1 (en) *	2002-06-14	2004-02-19	Agouron Pharmaceuticals, Inc.	Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
TWI276631B (en) *	2002-09-12	2007-03-21	Avanir Pharmaceuticals	Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
AU2003270426A1 (en)	2002-09-12	2004-04-30	Avanir Pharmaceuticals	PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
WO2004065370A1 (en) *	2003-01-23	2004-08-05	Crystalgenomics, Inc.	Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof
WO2004093873A1 (en) *	2003-04-17	2004-11-04	Janssen Pharmaceutica, N.V.	2-phenyl-benzimidazol and 2-phenyl-imidazo-`4,5!-pyridine derivatives as checkpoint kinase cds1 (chk2) inhibitors for the treatment of cancer
CA2533990A1 (en) *	2003-08-08	2005-02-17	Avanir Pharmaceuticals	Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
US7728026B2 (en)	2005-04-11	2010-06-01	Abbott Laboratories, Inc.	2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
TWI375673B (en)	2005-04-11	2012-11-01	Abbott Lab	1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
EP1906948A4 (en)	2005-07-18	2010-03-17	Bipar Sciences Inc	TREATMENT OF CANCER
ES2380803T3 (es)	2005-11-14	2012-05-18	Centre National De La Recherche Scientifique (Cnrs)	Dominio no histona MACROH2A como inhibidor de la actividad PARP-1 y uso del mismo
EP1966157B1 (en)	2005-11-15	2010-03-24	Abbott Laboratories	Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
EP2329818A1 (en) *	2006-01-17	2011-06-08	Abbott Laboratories	Combination therapy with PARP inhibitors
US20080280867A1 (en) *	2006-01-17	2008-11-13	Abbott Laboratories	Combination therapy with parp inhibitors
US20080293795A1 (en) *	2006-01-17	2008-11-27	Abbott Laboratories	Combination therapy with parp inhibitors
US20090029966A1 (en) *	2006-01-17	2009-01-29	Abbott Laboratories	Combination therapy with parp inhibitors
US20080146638A1 (en) *	2006-01-17	2008-06-19	Abbott Laboratories	Combination therapy with parp inhibitors
US20090275619A1 (en) *	2006-04-03	2009-11-05	BOUERES Julia	Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
EP2012780B1 (en)	2006-05-02	2012-04-11	Abbott Laboratories	Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
US20080262062A1 (en) *	2006-11-20	2008-10-23	Bipar Sciences, Inc.	Method of treating diseases with parp inhibitors
US7994222B2 (en)	2006-09-05	2011-08-09	Bipar Sciences, Inc.	Monitoring of the inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds
CA2662517A1 (en)	2006-09-05	2008-03-13	Jerome Moore	Treatment of cancer
AU2007292302A1 (en) *	2006-09-05	2008-03-13	Bipar Sciences, Inc.	Methods for designing PARP inhibitors and uses thereof
US8071623B2 (en)	2007-01-10	2011-12-06	Instituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa	Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
US8067613B2 (en)	2007-07-16	2011-11-29	Abbott Laboratories	Benzimidazole poly(ADP ribose)polymerase inhibitors
US20090062268A1 (en) *	2007-08-27	2009-03-05	Lead Therapeutics, Inc.	Novel inhibitors of poly(adp-ribose)polymerase (parp)
CN101903025A (zh) *	2007-10-19	2010-12-01	彼帕科学公司	利用苯并吡喃酮-型parp抑制剂治疗癌症的方法和组合物
US7732491B2 (en)	2007-11-12	2010-06-08	Bipar Sciences, Inc.	Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
KR101653548B1 (ko)	2008-01-08	2016-09-02	머크 샤프 앤드 돔 리미티드	2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염
US20090275608A1 (en) *	2008-02-04	2009-11-05	Bipar Sciences, Inc.	Methods of diagnosing and treating parp-mediated diseases
WO2010083199A1 (en)	2009-01-19	2010-07-22	Abbott Laboratories	Benzthiazole inhibitors of poly(adp-ribose)polymerase
US20110218103A1 (en) *	2010-03-04	2011-09-08	Bayer Cropscience Ag	Fluoroalkyl-substituted 2-amidobenzimidazoles
CN102417483A (zh) *	2010-09-27	2012-04-18	中国药科大学	作为parp抑制剂的2-苯基-1h-苯并咪唑-4-甲酸酯衍生物
EP2561759A1 (en)	2011-08-26	2013-02-27	Bayer Cropscience AG	Fluoroalkyl-substituted 2-amidobenzimidazoles and their effect on plant growth
CN103130723B (zh) *	2011-11-30	2015-01-14	成都地奥制药集团有限公司	一种多聚(adp-核糖)聚合酶抑制剂
CN102627610B (zh) *	2012-04-11	2014-06-25	江苏先声药物研究有限公司	一类苯并咪唑类衍生物及其应用
EA201590482A1 (ru)	2012-09-05	2015-07-30	Байер Кропсайенс Аг	Применение замещенных 2-амидобензимидазолов, 2-амидобензоксазолов и 2-амидобензотиазолов или их солей в качестве биологически активных веществ против абиотического стресса растений
CN104140426B (zh) *	2013-05-07	2017-02-01	上海汇伦生命科技有限公司	嘧啶并咪唑类化合物、其药物组合物及其制备方法和用途
CN104230896A (zh)	2013-06-17	2014-12-24	上海汇伦生命科技有限公司	苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途
CN107556288A (zh) *	2016-07-01	2018-01-09	山东大学齐鲁医院	一种治疗转移性肿瘤的药物化合物
US10874641B2 (en)	2016-07-28	2020-12-29	Mitobridge, Inc.	Methods of treating acute kidney injury
RU2019114863A (ru)	2016-11-02	2020-12-03	Иммуноджен, Инк.	Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp
KR20200121800A (ko) *	2018-01-05	2020-10-26	싸이브렉사 1, 인크.	산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
WO2019195658A1 (en)	2018-04-05	2019-10-10	Dana-Farber Cancer Institute, Inc.	Sting levels as a biomarker for cancer immunotherapy
JP2022541749A (ja)	2019-07-10	2022-09-27	サイブレクサ２，インコーポレイテッド	治療薬としての細胞毒素のペプチドコンジュゲート
KR20220051332A (ko)	2019-07-10	2022-04-26	싸이브렉사 3, 인크.	치료제로서의 미세소관 표적화제의 펩티드 접합체
WO2021041532A1 (en)	2019-08-26	2021-03-04	Dana-Farber Cancer Institute, Inc.	Use of heparin to promote type 1 interferon signaling
CN111793034B (zh) *	2020-07-24	2021-11-19	华中科技大学	苯并咪唑盐衍生物与制备抗肿瘤药物的应用
US20240093250A1 (en)	2021-01-08	2024-03-21	Cybrexa 2, Inc.	Process for preparing a conjugate linking moiety
WO2022155172A1 (en)	2021-01-13	2022-07-21	Cybrexa 3, Inc.	Peptide conjugates of therapeutics

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1087561A (en) *	1963-02-16	1967-10-18	Fisons Pest Control Ltd	Fluorinated benzimidazoles and compositions containing them
DE3346575A1 (de) *	1983-12-23	1985-07-04	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue benzimidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel
DE3522230A1 (de) *	1985-06-21	1987-01-02	Thomae Gmbh Dr K	Neue 2-arylimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB8822483D0 (en) *	1988-09-24	1988-10-26	Medical Res Council	Developments relating to mas oncogene
GB8904174D0 (en) *	1989-02-23	1989-04-05	British Bio Technology	Compounds
IE70593B1 (en) *	1989-09-29	1996-12-11	Eisai Co Ltd	Biphenylmethane derivative the use of it and pharmacological compositions containing same
IL95975A (en) *	1989-10-24	1997-06-10	Takeda Chemical Industries Ltd	N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
WO1992005784A1 (en) *	1990-10-02	1992-04-16	Warner-Lambert Company	4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
US5216003A (en) *	1992-01-02	1993-06-01	G. D. Searle & Co.	Diacid-containing benzimidazole compounds for treatment of neurotoxic injury
AU675484B2 (en) *	1993-03-24	1997-02-06	Neurosearch A/S	Benzimidazole compounds, their use and preparation
US5824696A (en) *	1993-09-01	1998-10-20	Smithkline Beecham Corporation	Medicaments
US5735973A (en) *	1993-12-20	1998-04-07	Tamura Kaken Corporation	Printed circuit board surface protective agent
US5821258A (en) *	1994-12-27	1998-10-13	Mitsui Chemicals, Inc.	Phenylbenzimidazole derivatives

1996
- 1996-07-30 DE DE69624115T patent/DE69624115T2/de not_active Expired - Fee Related
- 1996-07-30 BR BR9610051-6A patent/BR9610051A/pt not_active Application Discontinuation
- 1996-07-30 NZ NZ313713A patent/NZ313713A/en unknown
- 1996-07-30 PL PL96324869A patent/PL324869A1/xx unknown
- 1996-07-30 WO PCT/GB1996/001832 patent/WO1997004771A1/en not_active Application Discontinuation
- 1996-07-30 EA EA199800184A patent/EA000999B1/ru not_active IP Right Cessation
- 1996-07-30 JP JP9507360A patent/JPH11510154A/ja not_active Ceased
- 1996-07-30 HU HU9901092A patent/HUP9901092A3/hu not_active Application Discontinuation
- 1996-07-30 ES ES96925875T patent/ES2183004T3/es not_active Expired - Lifetime
- 1996-07-30 AP APAP/P/1998/001183A patent/AP866A/en active
- 1996-07-30 EP EP96925875A patent/EP0841924B1/en not_active Expired - Lifetime
- 1996-07-30 DK DK96925875T patent/DK0841924T3/da active
- 1996-07-30 KR KR10-1998-0700752A patent/KR100447539B1/ko not_active IP Right Cessation
- 1996-07-30 PT PT96925875T patent/PT841924E/pt unknown
- 1996-07-30 AT AT96925875T patent/ATE225173T1/de not_active IP Right Cessation
- 1996-07-30 AU AU66240/96A patent/AU714873B2/en not_active Ceased
- 1996-07-30 SK SK135-98A patent/SK13598A3/sk unknown
- 1996-07-30 TR TR1998/00127T patent/TR199800127T1/xx unknown
- 1996-07-30 CA CA002225465A patent/CA2225465A1/en not_active Abandoned
- 1996-07-30 IL IL12314796A patent/IL123147A/en not_active IP Right Cessation
- 1996-07-30 CZ CZ98303A patent/CZ30398A3/cs unknown
- 1996-07-31 CN CNB961968818A patent/CN1159007C/zh not_active Expired - Fee Related
1998
- 1998-01-30 NO NO19980414A patent/NO317033B1/no not_active IP Right Cessation
- 1998-01-30 OA OA9800017A patent/OA10661A/en unknown
- 1998-02-02 MX MX9800927A patent/MX9800927A/es not_active IP Right Cessation
- 1998-02-02 US US09/017,314 patent/US6100283A/en not_active Expired - Fee Related
2000
- 2000-06-16 US US09/594,776 patent/US6310082B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN1195985A (zh)	1998-10-14
DE69624115D1 (de)	2002-11-07
CN1159007C (zh)	2004-07-28
AU6624096A (en)	1997-02-26
AP9801183A0 (en)	1998-01-31
EA199800184A1 (ru)	1998-10-29
AP866A (en)	2000-08-17
NO980414D0 (no)	1998-01-30
EA000999B1 (ru)	2000-08-28
KR19990036086A (ko)	1999-05-25
ATE225173T1 (de)	2002-10-15
EP0841924B1 (en)	2002-10-02
EP0841924A1 (en)	1998-05-20
NO317033B1 (no)	2004-07-26
CA2225465A1 (en)	1997-02-13
HUP9901092A2 (hu)	1999-07-28
KR100447539B1 (ko)	2004-11-10
IL123147A (en)	2004-02-19
OA10661A (en)	2002-11-25
CZ30398A3 (cs)	1998-06-17
DK0841924T3 (da)	2003-02-10
PL324869A1 (en)	1998-06-22
DE69624115T2 (de)	2003-06-18
PT841924E (pt)	2003-02-28
NO980414L (no)	1998-04-02
NZ313713A (en)	2001-03-30
BR9610051A (pt)	1999-12-21
WO1997004771A1 (en)	1997-02-13
US6310082B1 (en)	2001-10-30
US6100283A (en)	2000-08-08
IL123147A0 (en)	1998-09-24
MX9800927A (es)	1998-10-31
HUP9901092A3 (en)	2001-11-28
ES2183004T3 (es)	2003-03-16
TR199800127T1 (xx)	1998-04-21
AU714873B2 (en)	2000-01-13
JPH11510154A (ja)	1999-09-07

Publication	Publication Date	Title
SK13598A3 (en)	1998-06-03	Benzimidazole compounds
US6316455B1 (en)	2001-11-13	Method of improving the effectiveness of a cytotoxic drug or radiotherapy using a quinazolinone compound
HU219343B (en)	2001-03-28	Process for producing acylated arylalkylamine derivatives and pharmaceutical compositiions comprising them
CN105669520B (zh)	2018-10-30	含有色氨酸基本骨架的邻苯二胺类选择性组蛋白去乙酰化酶抑制剂及其制备方法和应用
SK15222001A3 (sk)	2002-06-04	Cykloalkylsubstituované benzimidazoly, ich príprava a použitie
RU2282627C2 (ru)	2006-08-27	Кумариновые производные с подавляющей комт активностью
CN108409608B (zh)	2020-11-03	芳香氮芥类组蛋白去乙酰化酶抑制剂及其制备方法和应用
CN114524799B (zh)	2023-05-26	一种hdac抑制剂及其制备方法和用途
CN113754587B (zh)	2023-07-14	一种苯基吡唑类化合物及应用
US10954197B2 (en)	2021-03-23	Cathepsin-D and angiogenesis inhibitors and compositions thereof for treating breast cancer
AU758194B2 (en)	2003-03-20	Novel benzimidazoles and benzoxazoles
CN115819349A (zh)	2023-03-21	一种吡唑类化合物及其制备方法和应用
CN118063489A (zh)	2024-05-24	吴茱萸碱类化合物及其制药用途